Newborn screening for cystic fibrosis - lessons from national programmes in Europe

J. Barben (St. Gallen, Switzerland)

Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children
Session: PG10 Cystic fibrosis: Basic defects and clinical problems in children
Session type: Postgraduate Course
Number: 105
Disease area: Paediatric lung diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Barben (St. Gallen, Switzerland). Newborn screening for cystic fibrosis - lessons from national programmes in Europe. International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Newborn screening for cystic fibrosis: opportunities and remaining challenges
Source: Eur Respir Monogr 2014; 64: 65-76
Year: 2014


Newborn screening in Europe
Source: Research Seminar 2006 - Preventing respiratory sequelae in children diagnosed with cystic fibrosis by newborn screening
Year: 2006


Public awareness on cystic fibrosis: results from a national pragmatic survey
Source: Eur Respir J 2015; 46: 264-267
Year: 2015


Case study in cystic fibrosis: the US CF Foundation research and clinical development programmes
Source: Research Seminar 2014 - Breaking down barriers to lung health: a better environment for better medicines
Year: 2014


1-PRO "Newborn screening for cystic fibrosis should be added to routine newborn screening programmes"
Source: Annual Congress 2010 - Pro/Con debates: 1. To screen or not to screen for cystic fibrosis: is it still the question, 2. Specific immunotherapy for asthma
Year: 2010

Need for early intervention in cystic fibrosis - impact of an educational programme
Source: Eur Respir J 2005; 26: Suppl. 49, 621s
Year: 2005

Cystic fibrosis newborn screening programme in central Catalonia area (Spain). What have we learnt 8 years later?
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008


Impact of the SARS-CoV-2 pandemic on cystic fibrosis centres and care: survey results from US centres
Source: ERJ Open Res, 7 (4) 00249-2021; 10.1183/23120541.00249-2021
Year: 2021



Cohort analysis of a large community-based latent tuberculosis screening and treatment programme in a high incidence setting in East London
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016

Challenges of providing care to adults with cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 286-303
Year: 2014


Notified or missed cases? An assessment of successful linkage for referred tuberculosis patients in South India
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015

DNA-based screening for CF: which protocol is best in a multiethnic Europe? Lessons from the UK experience
Source: Eur Respir J 2002; 20: Suppl. 38, 340s
Year: 2002

Tuberculosis screening of migrants to low-burden nations: insights from evaluation of UK practice
Source: Eur Respir J 2011; 37: 1175-1182
Year: 2011



Did the tobacco industry know that smoking caused cystic fibrosis-like lung disease before the scientific community?
Source: International Congress 2015 – Emerging data on (e-)cigarettes and their health hazards
Year: 2015

Future trends in cystic fibrosis demography in 34 European countries
Source: Eur Respir J 2015; 46: 133-141
Year: 2015



Implementation of supervised physiotherapy in a school environment in children with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015


The German cystic fibrosis quality assurance project: clinical features in children and adults
Source: Eur Respir J 2001; 17: 1187-1194
Year: 2001



Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs)
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016

Screening immigrants to Ireland from countries with a high prevalence of tuberculosis would be clinically beneficial and cost effective
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013


Should the D1152H variant be included in cystic fibrosis newborn screening programmes?
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020